IC-100 (InflamaCORE/ZyVersa Therapeutics)

N/A

Report date: 2025/04/10 15:20:15

Base Information

Drug NameIC-100 (InflamaCORE/ZyVersa Therapeutics)
Drug Alias NameIC 100-01IC 100-02IC 100-03IC 100-04IC 100-05 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionInflammasomes inhibitorsCytokines inhibitorsApoptosis-associated speck-like protein containing a CARD inhibitors
TargetsInflammasomesCytokinesApoptosis-associated speck-like protein containing a CARD
Therapy Area/IndicationsHeart FailureGlomerulonephritis, IGAAlzheimer Disease +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInflamacore LLCUniversity Of Miami
China Registration ClassN/A

Develop Information

Active CompaniesZyVersa Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsHeart FailureGlomerulonephritis, IGAAlzheimer Disease +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A